TGF Beta R1 Antibody, Cy3 Conjugated

Cy3

7046

None

P36897

Cytoplasm

anticorps

Unmodified

Polyclonal

310-360/501

1ug per 1ul

FCM, IF(IHC-P)

Human, Mouse, Rat

cy3 conjugation kit

512,550nm/570,615nm

TGF beta Receptor I

Polyclonal antibody

Conjugated Primary Antibodies

Rabbit (Oryctolagus cuniculus)

FCM(1:20-100), IF(IHC-P)(1:50-200)

This antibody was purified via Protein A.

TGF Beta R1 Polyclonal Antibody, Cy3 Conjugated

This is a highly specific antibody against TGF beta Receptor I.

KLH conjugated synthetic peptide derived from human TGF-beta R1

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Keep the antibody in an aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store refrigerated at 2 to 8 degrees Celcius for up to 1 year.

AAT5; ALK5; ESS1; LDS1; MSSE; SKR4; ALK-5; LDS1A; LDS2A; TGFR-1; ACVRLK4; TGF-beta receptor type-1; Activin A receptor type II-like protein kinase of 53kD; Activin receptor-like kinase 5; Serine/threonine-protein kinase receptor R4; TGF-beta type I receptor; Transforming growth factor-beta receptor type I; TGF-beta receptor type I; TbetaR-I; TGFBR1

If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.Cy3 antibodies are excited by the 488-nanometer wave of an argon laser and the 633-nanometer line of a helium-neon diode laser. 1 of the Anti-TGF beta Receptor I can be used in flow cytometry but typically shows lower fluorescence intensity comparable to that of PE or APC. This Bioss Primary Conjugated Antibodies antibody is well suited for fluorescent microscopy.

Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation.